Multiple myeloma and lymphoma cell lines
RPMI-8226, Kas6,
Daudi, and
SUDHL4, were from American Type Culture Collection (ATCC, Manassas, VA). To generate
bortezomib-refractory cells, parental
RPMI-8226 or Kas6 cells (designated as RMPI-8226wt or Kas6wt) were chronically exposed to increasing concentrations of
bortezomib to generate resistant lines (designated as RMPI-8226v10r or Kas6v10r)
[29 (link),30 (link)]. Resistant lines were then cultured in the presence of 10 nM
bortezomib. Cell line identities were confirmed by Short Tandem Repeat DNA profiling as conducted by the MD Anderson Cancer Center Characterized Cell Line Core. All cell lines were cultured in
RPMI1640 (Thermo Fisher Scientific, Waltham, MA) with 10%
FBS (Thermo Fisher Scientific, Waltham, MA), 1%
L-glutamine (Thermo Fisher Scientific, Waltham, MA), and 1%
penicillin/streptomycin (Lonza, Basel, Switzerland) at 37 °C in a 5% CO
2 incubator. All cultures were free of bacterial, fungal, and mycoplasma contamination (mycoplasma contamination was tested every 6 months). The following drugs were used for the study:
bortezomib, LC Laboratories, (Woburn, MA);
vorinostat, Cayman Chemical, (Ann Arbor, MI);
panobinostat, LC Laboratories, (Woburn, MA);
ricolinostat, Selleck Chemicals, (Houston, TX);
tubacin, Selleck Chemicals, (Houston, TX).
Cheng T., Kiser K., Grasse L., Iles L., Bartholomeusz G., Samaniego F., Orlowski R.Z, & Chandra J. (2021). Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat. Cancer Drug Resistance, 4(4), 888-902.